Cyclerion Soars 400% After $380M Merger With Korsana Biosciences

Shares of Cyclerion Therapeutics surged by over 400% on Wednesday after the company announced a merger with Korsana Biosciences. The deal, structured as a reverse takeover, will see the combined business rebranded under the Korsana name and listed on Nasdaq with the new ticker 'KRSA'. The all-stock merger marks the end of a strategic review for Cyclerion, a small-cap biotech with limited operations. Under the agreement, Cyclerion's existing shareholders will hold just 1.5% of the new entity, while Korsana's investors will take a 98.5% stake. The company's most recent financial report showed $2.07 million in revenue and a net loss of $3.53 million.

A private investment round (PIPE) raised around $380 million, far exceeding expectations. The funding was led by Fairmount and Venrock Healthcare Capital Partners, with contributions from JPMorgan, Janus Henderson, and Sanofi Ventures. These funds are expected to support operations through 2029. Korsana's lead drug candidate, KRSA-028, targets Alzheimer's but remains in early development. No human efficacy data is anticipated before late 2027. Existing Cyclerion shareholders will receive contingent value rights (CVRs) linked to legacy assets, while Korsana insiders face a 180-day lock-up period post-merger. Jonathan Violin, Korsana's current CEO, will lead the combined company. Tomas Kiselak from Fairmount will serve as chairman.

The merger transforms Cyclerion into Korsana Biosciences, a newly funded entity with a Nasdaq listing. The $380 million capital raise secures long-term financing, while the drug pipeline remains in early stages. Shareholders and leadership roles have been restructured as part of the deal.